Individualization of anti-VEGF treatment protocols can reduce treatment burden on patients with age-related macular degeneration ... hemorrhages or fluid seen on OCT images.

LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...

The 2024 American Academy of Ophthalmology (AAO) Preferred Practice Patterns provide guidance for physicians about best practices in the treatment of age-related macular degeneration (AMD).

Patients with neovascular age-related macular degeneration (nAMD ... and intraretinal fluid (IRF). Optical coherence tomography was taken as well. There were 35 eyes from 35 patients that were ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ranibizumab, is delivered through an ocular implant that is refilled every nine ...

Thanks to advancements in early detection and treatment options, it's possible to live a long and healthy life after being ...

Purpose To analyse the morphological characteristics of eyes with neovascular age-related macular degeneration (AMD ... years of follow-up after initiating anti-VEGF therapy. Spectral-domain optical ...

Age-related macular degeneration (AMD) is still referred to as the ... Simultaneously, ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows ...

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized ... These include: Eylea HD (aflibercept), approved in August 2023 Vabysmo (faricimab), approved in October 2023 ...